|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0024554,
umls-concept:C0031327,
umls-concept:C0032177,
umls-concept:C0042960,
umls-concept:C0178602,
umls-concept:C0205171,
umls-concept:C0205385,
umls-concept:C0442027,
umls-concept:C0528714,
umls-concept:C0528716,
umls-concept:C0851347,
umls-concept:C1549078,
umls-concept:C1997894
|
|
pubmed:issue |
5
|
|
pubmed:dateCreated |
1999-7-6
|
|
pubmed:abstractText |
This study constituted the first administration of the oral platelet inhibitor, sibrafiban, to humans. The aim was to investigate the pharmacokinetics and pharmacodynamics of Ro 44-3888, the active principle of sibrafiban, after single ascending oral doses of sibrafiban. Particular emphasis was placed on intersubject variability of the pharmacokinetic and pharmacodynamic parameters of Ro 44-3888.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Adenosine Diphosphate,
http://linkedlifedata.com/resource/pubmed/chemical/Amidines,
http://linkedlifedata.com/resource/pubmed/chemical/Heterocyclic Compounds,
http://linkedlifedata.com/resource/pubmed/chemical/Oximes,
http://linkedlifedata.com/resource/pubmed/chemical/Peptide Fragments,
http://linkedlifedata.com/resource/pubmed/chemical/Piperidines,
http://linkedlifedata.com/resource/pubmed/chemical/Platelet Aggregation Inhibitors,
http://linkedlifedata.com/resource/pubmed/chemical/Platelet Glycoprotein GPIIb-IIIa...,
http://linkedlifedata.com/resource/pubmed/chemical/Prodrugs,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Thrombin,
http://linkedlifedata.com/resource/pubmed/chemical/Ro 44-3888,
http://linkedlifedata.com/resource/pubmed/chemical/Ro 48-3656,
http://linkedlifedata.com/resource/pubmed/chemical/sibrafiban
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
May
|
|
pubmed:issn |
0306-5251
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
47
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
521-30
|
|
pubmed:dateRevised |
2009-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:10336576-Adenosine Diphosphate,
pubmed-meshheading:10336576-Administration, Oral,
pubmed-meshheading:10336576-Adult,
pubmed-meshheading:10336576-Amidines,
pubmed-meshheading:10336576-Area Under Curve,
pubmed-meshheading:10336576-Contusions,
pubmed-meshheading:10336576-Dose-Response Relationship, Drug,
pubmed-meshheading:10336576-Double-Blind Method,
pubmed-meshheading:10336576-Heterocyclic Compounds,
pubmed-meshheading:10336576-Humans,
pubmed-meshheading:10336576-Male,
pubmed-meshheading:10336576-Oximes,
pubmed-meshheading:10336576-Peptide Fragments,
pubmed-meshheading:10336576-Piperidines,
pubmed-meshheading:10336576-Platelet Aggregation,
pubmed-meshheading:10336576-Platelet Aggregation Inhibitors,
pubmed-meshheading:10336576-Platelet Glycoprotein GPIIb-IIIa Complex,
pubmed-meshheading:10336576-Prodrugs,
pubmed-meshheading:10336576-Receptors, Thrombin
|
|
pubmed:year |
1999
|
|
pubmed:articleTitle |
Pharmacokinetics and pharmacodynamics of Ro 44-3888 after single ascending oral doses of sibrafiban, an oral platelet aggregation inhibitor, in healthy male volunteers.
|
|
pubmed:affiliation |
Department of Clinical Pharmacology, F. Hoffmann-La Roche Ltd, Grenzacherstrasse 124, 4070 CH-Basel.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Controlled Clinical Trial
|
